Company plans to meet with FDA regarding potential sNDA submission in 1H 2025 Call planned today at 8:30 a.m. (ET) to discuss company’s diabetes program progression DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Dec. 16, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company
","language":"en","releaseDate":{"dateUTC":"2024-12-16T11:05:00","date":"2024-12-16T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/20181/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-12-16T11:05:20","lastUpdatedUTC":"2024-12-16T16:56:22"},{"id":20171,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/20171","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/cdsco-approves-afrezzar-insulin-human-inhalation-powder-india"},"title":"CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India","type":{"title":"General","id":3886},"teaser":"India has the 2 nd highest burden of diabetes worldwide CDSCO decision follows existing approvals in the U.S.A. and Brazil MannKind expects to ship product for Cipla Ltd. by end of 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Dec. 11, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:","language":"en","releaseDate":{"dateUTC":"2024-12-11T11:00:00","date":"2024-12-11T06:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/20171/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-12-11T11:00:41","lastUpdatedUTC":"2024-12-11T11:00:41"},{"id":20131,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/20131","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2024-third-quarter-financial"},"title":"MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 4:30 p.m. (ET) 3Q 2024 Total revenues of $70M ; +37% vs. 3Q 2023 YTD 2024 Total revenues of $209M ; +49% vs. YTD 2023 YTD 2024 Net income of $20 million ; Non-GAAP net income of $45 million Orphan lung disease studies proceeding as planned MNKD-101 Phase 3","language":"en","releaseDate":{"dateUTC":"2024-11-07T21:02:00","date":"2024-11-07T16:02:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/20131/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-11-07T21:02:42","lastUpdatedUTC":"2024-11-07T21:02:42"},{"id":20116,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/20116","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-present-2024-ubs-healthcare-conference"},"title":"MannKind to Present at 2024 UBS Healthcare Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced","language":"en","releaseDate":{"dateUTC":"2024-11-05T21:15:00","date":"2024-11-05T16:15:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind to Present at 2024 UBS Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/20116/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-11-05T21:15:38","lastUpdatedUTC":"2024-11-05T21:15:38"},{"id":20096,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/20096","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-successfully-completes-phase-1-trial-nintedanib-dpi"},"title":"MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases","type":{"title":"General","id":3886},"teaser":"Met primary objective demonstrating nintedanib DPI was safe and well tolerated Participants did not experience adverse events typically reported with oral nintedanib Expect to meet with the FDA in 1H 2025 to advance MNKD-201 into the next phase of development DANBURY, Conn.","language":"en","releaseDate":{"dateUTC":"2024-11-04T11:05:00","date":"2024-11-04T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/20096/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-11-04T11:05:20","lastUpdatedUTC":"2024-11-04T11:05:20"},{"id":20086,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/20086","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2024-third-quarter-financial-results"},"title":"MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Oct. 31, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , announced today that its third quarter 2024 financial results will be released after market close on Thursday, November 7, 2024 . MannKind will host a webcast beginning at 4:30 p.m.","language":"en","releaseDate":{"dateUTC":"2024-10-31T20:05:00","date":"2024-10-31T16:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/20086/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-10-31T20:05:33","lastUpdatedUTC":"2024-10-31T20:05:33"},{"id":20081,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/20081","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/more-adults-type-1-diabetes-achieved-a1c-goal"},"title":"More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)","type":{"title":"General","id":3886},"teaser":"30-week results from the Phase 4 INHALE-3 study expand upon the positive 17-week data presented earlier this year at the American Diabetes Association’s 84 th Scientific Sessions Switching to, or remaining on Afrezza allowed twice as many people to get to goal during the extension phase DANBURY,","language":"en","releaseDate":{"dateUTC":"2024-09-30T10:00:00","date":"2024-09-30T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/20081/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-09-30T10:01:27","lastUpdatedUTC":"2024-09-30T10:01:27"},{"id":20076,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/20076","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-clearance-pmda-initiate-phase-3-clinical"},"title":"MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease","type":{"title":"General","id":3886},"teaser":"Clearance to proceed also received from health authorities in South Korea and Australia , with Taiwan expected in 4Q 2024 First U.S. patient randomized DANBURY, Conn. , Sept. 18, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and","language":"en","releaseDate":{"dateUTC":"2024-09-18T10:15:00","date":"2024-09-18T06:15:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/20076/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-09-18T10:15:26","lastUpdatedUTC":"2024-09-18T10:15:26"},{"id":20071,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/20071","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-present-2024-cantor-fitzgerald-global-healthcare"},"title":"MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Sept. 10, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced","language":"en","releaseDate":{"dateUTC":"2024-09-10T20:30:00","date":"2024-09-10T16:30:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/20071/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-09-10T20:32:47","lastUpdatedUTC":"2024-09-10T20:32:47"},{"id":20011,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/20011","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-present-upcoming-conferences-11"},"title":"MannKind to Present at Upcoming Conferences","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Aug. 27, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced","language":"en","releaseDate":{"dateUTC":"2024-08-27T20:30:00","date":"2024-08-27T16:30:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind to Present at Upcoming Conferences","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/20011/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-08-27T20:30:30","lastUpdatedUTC":"2024-08-27T20:30:30"},{"id":19976,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19976","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/kent-kresa-retire-mannkinds-board-directors-steven-b-binder-be"},"title":"Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Aug. 14, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced","language":"en","releaseDate":{"dateUTC":"2024-08-14T12:00:00","date":"2024-08-14T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19976/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-08-14T12:00:54","lastUpdatedUTC":"2024-08-14T12:00:54"},{"id":19961,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19961","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2024-second-quarter-financial"},"title":"MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 9:00 a.m. (ET) 2Q 2024 Total revenues of $72M ; +49% vs. 2Q 2023 YTD 2024 Total revenues of $139M ; +55% vs. YTD 2023 YTD 2024 Net income of $9 million ; Non-GAAP net income of $29 million Advances two orphan lung programs to human studies MNKD-101 Phase 3 clinical","language":"en","releaseDate":{"dateUTC":"2024-08-07T12:00:00","date":"2024-08-07T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19961/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-08-07T12:00:50","lastUpdatedUTC":"2024-08-07T12:00:50"},{"id":19956,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19956","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-launches-educational-website-raise-awareness-ntm-lung"},"title":"MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease","type":{"title":"General","id":3886},"teaser":"LearnAboutNTM.com provides information and resources for patients and caregivers Site launch in support of World NTM Awareness Day, August 4 DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , July 31, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development","language":"en","releaseDate":{"dateUTC":"2024-07-31T10:30:00","date":"2024-07-31T06:30:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19956/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-07-31T10:32:14","lastUpdatedUTC":"2024-07-31T10:32:14"},{"id":19951,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19951","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2024-second-quarter-financial-results"},"title":"MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , July 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , announced today that it will report its second quarter 2024 financial results before the market opens on Wednesday, August 7, 2024 . A press release detailing the quarterly results","language":"en","releaseDate":{"dateUTC":"2024-07-30T20:30:00","date":"2024-07-30T16:30:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19951/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-07-30T20:30:17","lastUpdatedUTC":"2024-07-30T20:30:17"},{"id":19891,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19891","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/inhale-3-study-reveals-positive-readout-head-head-comparison"},"title":"INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions","type":{"title":"General","id":3886},"teaser":"Study proves inhaled insulin is as effective as usual care (primarily automated insulin delivery pumps or multiple daily injections) for adults living with T1D meeting the primary endpoint Patients utilizing inhaled insulin reached target A1c (less than 7%) 30% of the time compared to 17% with","language":"en","releaseDate":{"dateUTC":"2024-06-22T12:00:00","date":"2024-06-22T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19891/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-06-22T12:00:29","lastUpdatedUTC":"2024-06-22T12:49:26"},{"id":19881,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19881","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/inhale-3-study-results-be-presented-during-90-minute-symposium"},"title":"Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions","type":{"title":"General","id":3886},"teaser":"17-week endpoint results comparing Afrezza ® head-to-head with multiple daily injections (MDI) and insulin pumps INHALE- 3 Study Protocol Chair Dr. Irl. B. Hirsh joined by investigational team to deliver presentation moderated by Jaeb Center founder Dr. Roy W. Beck DANBURY, Conn.","language":"en","releaseDate":{"dateUTC":"2024-06-05T10:45:00","date":"2024-06-05T06:45:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19881/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-06-05T10:45:37","lastUpdatedUTC":"2024-06-05T10:45:37"},{"id":19871,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19871","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-establish-boston-area-research-development-foothold-and"},"title":"MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix","type":{"title":"General","id":3886},"teaser":"Immediate opportunity to increase capacity for formulation and early asset development in upgraded Boston area R&D space Non-cash deal includes royalty-free iSPERSE ™ technology license in exchange for access to MannKind’s Cricket ® inhaler DANBURY, Conn. and WESTLAKE VILLAGE, Calif.","language":"en","releaseDate":{"dateUTC":"2024-05-29T12:45:00","date":"2024-05-29T08:45:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19871/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-05-29T12:47:17","lastUpdatedUTC":"2024-05-29T12:47:17"},{"id":19721,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19721","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2024-first-quarter-financial"},"title":"MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 p.m. (ET) 1Q 2024 Total revenues of $66M ; +63% vs. 1Q 2023 1Q 2024 Net income of $11M ; Non-GAAP net income of $15M $304M of cash and cash equivalents and investments at March 31, 2024 In early April, repaid Midcap senior-secured debt and Mann Group","language":"en","releaseDate":{"dateUTC":"2024-05-08T20:18:00","date":"2024-05-08T16:18:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19721/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-05-08T20:19:02","lastUpdatedUTC":"2024-05-08T20:19:02"},{"id":19696,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19696","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-receives-us-fda-fast-track-designation-clofazimine"},"title":"MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , May 06, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced","language":"en","releaseDate":{"dateUTC":"2024-05-06T10:05:00","date":"2024-05-06T06:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19696/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-05-06T10:05:16","lastUpdatedUTC":"2024-05-06T10:05:16"},{"id":19686,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19686","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2024-first-quarter-financial-results"},"title":"MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , May 01, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2024 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on","language":"en","releaseDate":{"dateUTC":"2024-05-01T20:00:00","date":"2024-05-01T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19686/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-05-01T20:00:42","lastUpdatedUTC":"2024-05-01T20:00:42"},{"id":19676,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19676","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-proceed-phase-1-nintedanib-dpi-mnkd-201-study-pulmonary"},"title":"MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases","type":{"title":"General","id":3886},"teaser":"First-in-human study to evaluate safety, tolerability and pharmacokinetics (PK) in healthy volunteers Enrollment of first study participant anticipated in June 2024 DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , April 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company","language":"en","releaseDate":{"dateUTC":"2024-04-30T10:05:00","date":"2024-04-30T06:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19676/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-04-30T10:05:27","lastUpdatedUTC":"2024-04-30T10:05:27"},{"id":19671,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19671","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-ind-clearance-us-fda-start-phase-3-study"},"title":"MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , April 29, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced","language":"en","releaseDate":{"dateUTC":"2024-04-29T10:05:00","date":"2024-04-29T06:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19671/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-04-29T10:07:30","lastUpdatedUTC":"2024-04-29T10:07:30"},{"id":19641,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19641","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-repays-certain-debt-obligations"},"title":"MannKind Repays Certain Debt Obligations","type":{"title":"General","id":3886},"teaser":"Credit and security agreement with MidCap Financial Trust repaid in full for approximately $31.6 million Convertible note issued to Mann Group LLC repaid in exchange for 1.5 million shares of common stock and approximately $8.9 million Total debt reduced since December 31, 2023 is approximately","language":"en","releaseDate":{"dateUTC":"2024-04-03T10:00:00","date":"2024-04-03T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Repays Certain Debt Obligations","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19641/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-04-03T10:00:30","lastUpdatedUTC":"2024-04-03T10:00:30"},{"id":19626,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19626","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-cfo-transition"},"title":"MannKind Announces CFO Transition","type":{"title":"General","id":3886},"teaser":"Steven B. Binder announces planned retirement and is appointed Executive Vice President, Special Projects, effective April 22, 2024 , through December 31, 2024 Christopher Prentiss appointed Chief Financial Officer, effective April 22, 2024 DANBURY, Conn. and WESTLAKE VILLAGE, Calif.","language":"en","releaseDate":{"dateUTC":"2024-03-26T20:05:00","date":"2024-03-26T16:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Announces CFO Transition","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19626/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-03-26T20:05:27","lastUpdatedUTC":"2024-03-26T20:05:27"},{"id":19616,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19616","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/inhale-3-studys-initial-meal-challenge-results-comparing"},"title":"INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps","type":{"title":"General","id":3886},"teaser":"Post-meal hyperglycemia was significantly reduced by 20% with inhaled insulin compared with rapid-acting insulin delivered through MDI or insulin pumps Subjects utilizing inhaled insulin experienced a 22% decrease in mean glucose excursions in the first two hours compared to the standard of care","language":"en","releaseDate":{"dateUTC":"2024-03-11T10:05:00","date":"2024-03-11T06:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19616/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-03-11T10:07:20","lastUpdatedUTC":"2024-03-11T10:07:20"},{"id":19606,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19606","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-new-clinical-data-inhale-3-study-be-presented"},"title":"MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8","type":{"title":"General","id":3886},"teaser":"Dr. Hirsch to present meal challenge results when switching from multiple daily injections (MDI) or insulin pumps to inhaled insulin (Afrezza® (insulin human) Inhalation Powder) DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , March 05, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a","language":"en","releaseDate":{"dateUTC":"2024-03-05T11:05:00","date":"2024-03-05T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19606/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-03-05T11:07:22","lastUpdatedUTC":"2024-03-05T11:07:22"},{"id":19601,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19601","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-announces-participation-upcoming-0"},"title":"MannKind Corporation Announces Participation at Upcoming Conferences","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. and DANBURY, Conn. , March 04, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it","language":"en","releaseDate":{"dateUTC":"2024-03-04T18:01:00","date":"2024-03-04T13:01:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Announces Participation at Upcoming Conferences","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19601/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-03-04T18:01:19","lastUpdatedUTC":"2024-03-04T18:01:19"},{"id":19581,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19581","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2023-fourth-quarter-and-full-year"},"title":"MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 p.m. (ET) 2023 Total revenues of $199M ; +99% vs. 2022 4Q 2023 Total revenues of $58M ; +62% vs. 2022 4Q 2023 Net income of $1M ; Non-GAAP net income of $7M $302M of cash and cash equivalents and investments at December 31, 2023 DANBURY, Conn.","language":"en","releaseDate":{"dateUTC":"2024-02-27T21:00:00","date":"2024-02-27T16:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19581/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-02-27T21:00:25","lastUpdatedUTC":"2024-02-27T21:00:25"},{"id":19561,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19561","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2023-fourth-quarter-and-full-year"},"title":"MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Feb. 20, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 fourth quarter and full year financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM (Eastern","language":"en","releaseDate":{"dateUTC":"2024-02-20T11:00:00","date":"2024-02-20T06:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19561/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-02-20T11:01:02","lastUpdatedUTC":"2024-02-20T11:01:02"},{"id":19556,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19556","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-enrollment-goal-completion-inhale-1-pediatric"},"title":"MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®","type":{"title":"General","id":3886},"teaser":"Reached enrollment goal of 305 patients living with Type 1 or Type 2 diabetes Primary endpoint analysis expected in 4Q 2024 Data dissemination and FDA submission expected in 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Feb. 15, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a","language":"en","releaseDate":{"dateUTC":"2024-02-15T11:05:00","date":"2024-02-15T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19556/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-02-15T11:07:28","lastUpdatedUTC":"2024-02-15T11:07:28"},{"id":19476,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19476","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-and-sagard-healthcare-enter-royalty-purchase-agreement"},"title":"MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million","type":{"title":"General","id":3886},"teaser":"Sagard Healthcare purchased a 1% royalty in Tyvaso DPI ® net sales Purchase price of $150 million ; additional potential milestone payment of up to $50 million WESTLAKE VILLAGE, Calif. , Jan. 02, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that on December 27, 2023 it","language":"en","releaseDate":{"dateUTC":"2024-01-02T11:05:00","date":"2024-01-02T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19476/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2024-01-02T11:07:17","lastUpdatedUTC":"2024-01-02T11:07:17"},{"id":19471,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19471","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-present-42nd-annual-jp-morgan-healthcare"},"title":"MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Dec. 28, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief","language":"en","releaseDate":{"dateUTC":"2023-12-28T11:00:00","date":"2023-12-28T06:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19471/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-12-28T11:00:19","lastUpdatedUTC":"2023-12-28T11:00:19"},{"id":19426,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19426","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2023-third-quarter-financial"},"title":"MannKind Corporation Reports 2023 Third Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 p.m. (ET) 3Q 2023 Total revenues of $51M ; +56% vs. 3Q 2022 3Q YTD 2023 Total revenues of $140M ; +121% vs. 3Q YTD 2022 3Q 2023 Net income of $2M ; Non-GAAP net income of $4M 3Q 2023 Tyvaso DPI royalties of $20M ; +225% vs.","language":"en","releaseDate":{"dateUTC":"2023-11-07T21:00:00","date":"2023-11-07T16:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2023 Third Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19426/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-11-07T21:00:28","lastUpdatedUTC":"2023-11-07T21:00:28"},{"id":19411,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19411","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-completion-enrollment-us-phase-4-inhale-3"},"title":"MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes","type":{"title":"General","id":3886},"teaser":"Rapidly enrolled 141 patients in less than four months Large study will compare A1c from baseline to 17 weeks for adults when switching from injectable insulin or pumps to inhaled insulin (Afrezza ® (insulin human) Inhalation Powder) Initial standardized meal data from INHALE-3 on target for","language":"en","releaseDate":{"dateUTC":"2023-11-06T11:15:00","date":"2023-11-06T06:15:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19411/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-11-06T11:17:11","lastUpdatedUTC":"2023-11-06T11:17:11"},{"id":19386,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19386","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2023-third-quarter-financial-results"},"title":"MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Oct. 31, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 third quarter financial results and year to date financial results and its management will host a conference call to discuss these results and corporate updates","language":"en","releaseDate":{"dateUTC":"2023-10-31T20:00:00","date":"2023-10-31T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19386/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-10-31T20:00:27","lastUpdatedUTC":"2023-10-31T20:00:27"},{"id":19381,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19381","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-expands-patent-portfolio-new-clofazimine-formulation"},"title":"MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent","type":{"title":"General","id":3886},"teaser":"Patent covers compositions of clofazimine, and methods for treating lung infections Development of MNKD-101 (inhaled clofazimine) continues for the potential treatment of nontuberculous mycobacterial (NTM) lung disease DANBURY, Conn. , Oct. 30, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:","language":"en","releaseDate":{"dateUTC":"2023-10-30T10:15:00","date":"2023-10-30T06:15:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19381/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-10-30T10:17:05","lastUpdatedUTC":"2023-10-30T10:17:05"},{"id":19356,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19356","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-announces-participation-upcoming"},"title":"MannKind Corporation Announces Participation at Upcoming Conferences","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. and DANBURY, Conn. , Sept. 05, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it","language":"en","releaseDate":{"dateUTC":"2023-09-05T10:00:00","date":"2023-09-05T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Announces Participation at Upcoming Conferences","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19356/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-09-05T10:00:22","lastUpdatedUTC":"2023-09-05T10:00:22"},{"id":19291,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19291","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2023-second-quarter-financial"},"title":"MannKind Corporation Reports 2023 Second Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 p.m. (ET) 2Q 2023 Total revenues of $49M ; +157% vs. 2Q 2022 2Q 2023 Tyvaso DPI royalties of $19M ; +63% vs. 1Q 2023 2Q 2023 Endocrine Business Unit net revenues of $18M ; Afrezza net revenues +27% vs. 2Q 2022 2Q 2023 Income from operations of $2M ; Non-GAAP","language":"en","releaseDate":{"dateUTC":"2023-08-07T20:00:00","date":"2023-08-07T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2023 Second Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19291/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-08-07T20:00:28","lastUpdatedUTC":"2023-08-07T20:00:28"},{"id":19261,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19261","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-announces-participation-2023-wedbush"},"title":"MannKind Corporation Announces Participation in the 2023 Wedbush PacGrow Healthcare Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Aug. 01, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that its","language":"en","releaseDate":{"dateUTC":"2023-08-01T10:00:00","date":"2023-08-01T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Announces Participation in the 2023 Wedbush PacGrow Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19261/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-08-01T10:00:26","lastUpdatedUTC":"2023-08-01T10:00:26"},{"id":19256,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19256","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2023-second-quarter-financial-results"},"title":"MannKind Corporation to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , July 31, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 second quarter financial results and year to date financial results and its management will host a conference call to discuss these results and corporate updates","language":"en","releaseDate":{"dateUTC":"2023-07-31T20:00:00","date":"2023-07-31T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19256/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-07-31T20:00:16","lastUpdatedUTC":"2023-07-31T20:00:16"},{"id":19226,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19226","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-launches-inhale-3-study-address-most-important-unmet"},"title":"MannKind Launches Inhale-3 Study to Address the Most Important Unmet Need Today in Adults Living With Type 1 Diabetes (T1D)","type":{"title":"General","id":3886},"teaser":"Large trial in adults comparing A1c and mealtime control when switching from injectable insulin or pumps to inhaled insulin (Afrezza ® (insulin human) Inhalation Powder) Time-in-range during waking hours remains a challenge despite advances in diabetes technology Lack of mealtime control is the","language":"en","releaseDate":{"dateUTC":"2023-06-22T10:05:00","date":"2023-06-22T06:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Launches Inhale-3 Study to Address the Most Important Unmet Need Today in Adults Living With Type 1 Diabetes (T1D)","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19226/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-06-22T10:05:23","lastUpdatedUTC":"2023-06-22T10:05:23"},{"id":19221,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19221","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/governor-ned-lamont-tour-mannkind-june-12-it-reaches"},"title":"Governor Ned Lamont to Tour MannKind June 12 as It Reaches a Manufacturing Milestone","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. , June 11, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will host Connecticut Governor Ned Lamont for a tour of its headquarters on Monday, June 12 . The visit coincides with MannKind reaching a manufacturing milestone as it has successfully scaled-up operations for","language":"en","releaseDate":{"dateUTC":"2023-06-11T12:05:00","date":"2023-06-11T08:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Governor Ned Lamont to Tour MannKind June 12 as It Reaches a Manufacturing Milestone","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19221/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-06-11T12:07:18","lastUpdatedUTC":"2023-06-11T12:07:18"},{"id":19066,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19066","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/dr-burkhard-blank-joins-mannkind-executive-vice-president"},"title":"Dr. Burkhard Blank Joins MannKind as Executive Vice President of Research & Development and Chief Medical Officer","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. , May 24, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced Burkhard Blank , MD, has joined the company","language":"en","releaseDate":{"dateUTC":"2023-05-24T12:30:00","date":"2023-05-24T08:30:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Dr. Burkhard Blank Joins MannKind as Executive Vice President of Research & Development and Chief Medical Officer","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19066/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-05-24T12:30:43","lastUpdatedUTC":"2023-05-24T12:30:43"},{"id":18991,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18991","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-2023-rbc-capital-markets-global"},"title":"MannKind Corporation to Participate in the 2023 RBC Capital Markets Global Healthcare Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , May 10, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that its","language":"en","releaseDate":{"dateUTC":"2023-05-10T10:00:00","date":"2023-05-10T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in the 2023 RBC Capital Markets Global Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18991/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-05-10T10:00:38","lastUpdatedUTC":"2023-05-10T10:00:38"},{"id":18986,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18986","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/correction-mannkind-corporation-reports-2023-first-quarter"},"title":"CORRECTION -- MannKind Corporation Reports 2023 First Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 p.m. (ET) DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , May 09, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by MannKind Corporation (Nasdaq: MKND), please note in the second table, titled \"CONDENSED CONSOLIDATED BALANCE","language":"en","releaseDate":{"dateUTC":"2023-05-10T00:21:00","date":"2023-05-09T20:21:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"CORRECTION -- MannKind Corporation Reports 2023 First Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18986/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-05-10T00:22:09","lastUpdatedUTC":"2023-05-10T00:22:09"},{"id":18956,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18956","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2023-first-quarter-financial"},"title":"Mannkind Corporation Reports 2023 First Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 p.m. (ET) 1Q 2023 Total Revenues of $41 million ; +239% vs. 1Q 2022 1Q 2023 Revenues associated with Tyvaso DPI of $23 million 1Q 2023 Loss from operations decreased 72% vs. 1Q 2022 to $6 million $167 million of Cash, Cash Equivalents and Investments at","language":"en","releaseDate":{"dateUTC":"2023-05-09T20:00:00","date":"2023-05-09T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Mannkind Corporation Reports 2023 First Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18956/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-05-09T20:00:25","lastUpdatedUTC":"2023-05-09T20:00:25"},{"id":18926,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18926","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2023-first-quarter-financial-results"},"title":"MannKind Corporation to Hold 2023 First Quarter Financial Results Conference Call on May 9, 2023","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , May 02, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on","language":"en","releaseDate":{"dateUTC":"2023-05-02T21:00:00","date":"2023-05-02T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2023 First Quarter Financial Results Conference Call on May 9, 2023","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18926/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-05-02T21:00:21","lastUpdatedUTC":"2023-05-02T21:00:21"},{"id":18846,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18846","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/lauren-sabella-joins-mannkind-executive-vice-president-chief"},"title":"Lauren Sabella Joins Mannkind as Executive Vice President, Chief Operating Officer","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. , March 27, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced Lauren Sabella has joined the company as","language":"en","releaseDate":{"dateUTC":"2023-03-27T20:05:00","date":"2023-03-27T16:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Lauren Sabella Joins Mannkind as Executive Vice President, Chief Operating Officer","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18846/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-03-27T20:05:54","lastUpdatedUTC":"2023-03-27T20:05:54"},{"id":18836,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18836","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-oppenheimer-33rd-annual"},"title":"MannKind Corporation to Participate in Oppenheimer 33rd Annual Healthcare Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , March 07, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that","language":"en","releaseDate":{"dateUTC":"2023-03-07T22:00:00","date":"2023-03-07T17:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in Oppenheimer 33rd Annual Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18836/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-03-07T22:00:21","lastUpdatedUTC":"2023-03-07T22:00:21"},{"id":18811,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18811","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2022-fourth-quarter-and-full-year"},"title":"MannKind Corporation Reports 2022 Fourth Quarter and Full Year Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 p.m. (ET) 2022 Total Revenues of $100 million ; +32% vs. 2021 2022 Royalties from Tyvaso DPI of $16 million ; 4Q 2022 of $9 million 4Q 2022 Commercial Products Net Revenue of $17 million ;+54% vs. 4Q 2021 $173 million of Cash and Cash Equivalents and","language":"en","releaseDate":{"dateUTC":"2023-02-23T21:00:00","date":"2023-02-23T16:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2022 Fourth Quarter and Full Year Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18811/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-02-23T21:00:27","lastUpdatedUTC":"2023-02-23T21:00:27"},{"id":18796,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18796","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-give-oral-presentation-meal-challenge-results-afrezzar"},"title":"MannKind to Give Oral Presentation on Meal Challenge Results From the Afrezza® With Basal Combination (ABC Study) at 16th Annual ATTD Conference","type":{"title":"General","id":3886},"teaser":"Inhaled Technosphere ® Insulin (TI) lowered peak glucose levels 30 minutes faster than injectable rapid-acting insulin delivered through an AID insulin pump and significantly lowered post-prandial glucose (PPG) from 45-120 minutes after a controlled meal challenge test MannKind is planning a larger","language":"en","releaseDate":{"dateUTC":"2023-02-22T11:05:00","date":"2023-02-22T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind to Give Oral Presentation on Meal Challenge Results From the Afrezza® With Basal Combination (ABC Study) at 16th Annual ATTD Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18796/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-02-22T11:05:32","lastUpdatedUTC":"2023-02-22T11:05:32"},{"id":18791,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18791","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2022-fourth-quarter-and-full-year"},"title":"MannKind Corporation to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Feb. 16, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 fourth quarter and full year financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM (Eastern","language":"en","releaseDate":{"dateUTC":"2023-02-16T22:00:00","date":"2023-02-16T17:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18791/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-02-16T22:00:20","lastUpdatedUTC":"2023-02-16T22:00:20"},{"id":18776,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18776","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-svb-securities-global-biopharma"},"title":"Mannkind Corporation to Participate in the SVB Securities Global Biopharma Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Feb. 10, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that its","language":"en","releaseDate":{"dateUTC":"2023-02-10T22:00:00","date":"2023-02-10T17:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Mannkind Corporation to Participate in the SVB Securities Global Biopharma Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18776/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-02-10T22:00:18","lastUpdatedUTC":"2023-02-10T22:00:18"},{"id":18746,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18746","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-lytham-partners-investor-select"},"title":"MannKind Corporation to Participate in the Lytham Partners Investor Select Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Jan. 24, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that its","language":"en","releaseDate":{"dateUTC":"2023-01-24T11:00:00","date":"2023-01-24T06:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in the Lytham Partners Investor Select Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18746/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-01-24T11:00:27","lastUpdatedUTC":"2023-01-24T11:00:27"},{"id":18741,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18741","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkinds-inhaled-clofazimine-will-advance-adaptive-phase-23"},"title":"MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease","type":{"title":"General","id":3886},"teaser":"Direct delivery of clofazimine to the lungs may provide a treatment option for nontuberculous mycobacterial (NTM) lung disease that potentially overcomes systemic toxicity and lessens side effects Paper published on clofazimine inhalation suspension demonstrates promising tolerability and","language":"en","releaseDate":{"dateUTC":"2023-01-23T11:05:00","date":"2023-01-23T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18741/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-01-23T11:07:16","lastUpdatedUTC":"2023-01-23T11:07:16"},{"id":18726,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18726","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-present-2023-annual-jp-morgan-healthcare"},"title":"MannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Jan. 05, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief","language":"en","releaseDate":{"dateUTC":"2023-01-05T11:00:00","date":"2023-01-05T06:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18726/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-01-05T11:00:21","lastUpdatedUTC":"2023-01-05T11:00:21"},{"id":18716,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18716","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-present-two-posters-22nd-annual-diabetes-technology"},"title":"MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting","type":{"title":"General","id":3886},"teaser":"Technosphere ® Insulin (TI) peaked 30 minutes faster and significantly reduced postprandial glucose excursions (PPGE) at 60 minutes compared to subcutaneous insulins The Afrezza with Basal Combination (ABC) Study demonstrated similar glucose control between the three treatment groups; data to be","language":"en","releaseDate":{"dateUTC":"2022-11-10T11:05:00","date":"2022-11-10T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18716/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-11-10T11:09:28","lastUpdatedUTC":"2022-11-10T11:09:28"},{"id":18701,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18701","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2022-third-quarter-financial"},"title":"MannKind Corporation Reports 2022 Third Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 9:00 a.m. (ET) 3Q 2022 Total Revenues of $32.8 million ; +48% vs. 3Q 2021 3Q 2022 Royalties from Tyvaso DPI of $6.2 million 3Q 2022 Commercial Products Net Revenue of $16.3 million ; +67% vs. 3Q 2021 DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Nov.","language":"en","releaseDate":{"dateUTC":"2022-11-08T13:00:00","date":"2022-11-08T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2022 Third Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18701/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-11-08T13:00:55","lastUpdatedUTC":"2022-11-08T13:00:55"},{"id":18676,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18676","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2022-third-quarter-financial-results"},"title":"MannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Nov. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 third quarter and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 9:00 AM","language":"en","releaseDate":{"dateUTC":"2022-11-01T10:00:00","date":"2022-11-01T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18676/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-11-01T10:00:41","lastUpdatedUTC":"2022-11-01T10:00:41"},{"id":18656,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18656","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-lytham-partners-fall-2022"},"title":"MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Sept. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief","language":"en","releaseDate":{"dateUTC":"2022-09-21T21:00:00","date":"2022-09-21T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18656/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-09-21T21:00:47","lastUpdatedUTC":"2022-09-21T21:00:47"},{"id":18646,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18646","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-successfully-completes-phase-1-study-inhaled"},"title":"Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine","type":{"title":"General","id":3886},"teaser":"Study supports the dosing regimen that will be pursued in further clinical programs No serious adverse events or QT prolongation identified Planning underway to discuss results and the ongoing clinical program with the FDA DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Sept.","language":"en","releaseDate":{"dateUTC":"2022-09-06T10:15:00","date":"2022-09-06T06:15:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18646/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-09-06T10:15:24","lastUpdatedUTC":"2022-09-06T10:15:24"},{"id":18641,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18641","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-hc-wainwright-24th-annual"},"title":"MannKind Corporation to Participate in the H.C. Wainwright 24th Annual Global Investment Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Sept. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief","language":"en","releaseDate":{"dateUTC":"2022-09-01T10:00:00","date":"2022-09-01T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in the H.C. Wainwright 24th Annual Global Investment Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18641/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-09-01T10:00:16","lastUpdatedUTC":"2022-09-01T10:00:16"},{"id":18536,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18536","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2022-second-quarter-financial"},"title":"MannKind Corporation Reports 2022 Second Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 p.m. (ET) Tyvaso DPI™ approved by the FDA in May representing the second FDA-approved product using the Technosphere ® inhalation platform V-Go ® acquired May 31 ; $2.1 million Net Revenue recognized for June 2Q 2022 Commercial Products Net Revenue of $12.7","language":"en","releaseDate":{"dateUTC":"2022-08-09T20:00:00","date":"2022-08-09T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2022 Second Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18536/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-08-09T20:00:20","lastUpdatedUTC":"2022-08-09T20:00:20"},{"id":18516,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18516","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2022-second-quarter-financial-results"},"title":"MannKind Corporation to Hold 2022 Second Quarter Financial Results Conference Call on August 9, 2022","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Aug. 02, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 second quarter and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM","language":"en","releaseDate":{"dateUTC":"2022-08-02T10:00:00","date":"2022-08-02T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2022 Second Quarter Financial Results Conference Call on August 9, 2022","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18516/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-08-02T10:02:23","lastUpdatedUTC":"2022-08-02T10:02:23"},{"id":18491,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18491","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-btig-biotechnology-conference"},"title":"MannKind Corporation to Participate in the BTIG Biotechnology Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Aug. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief","language":"en","releaseDate":{"dateUTC":"2022-08-01T10:00:00","date":"2022-08-01T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in the BTIG Biotechnology Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18491/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-08-01T10:00:32","lastUpdatedUTC":"2022-08-01T10:00:32"},{"id":18486,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18486","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-host-product-theater-and-booth-american-diabetes"},"title":"Mannkind to Host Product Theater and Booth at the American Diabetes Association’s 82nd Scientific Sessions in New Orleans, June 3-7","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 03, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, will showcase its mealtime insulin solutions and","language":"en","releaseDate":{"dateUTC":"2022-06-03T14:00:00","date":"2022-06-03T10:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Mannkind to Host Product Theater and Booth at the American Diabetes Association’s 82nd Scientific Sessions in New Orleans, June 3-7","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18486/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-06-03T14:00:15","lastUpdatedUTC":"2022-06-03T15:57:40"},{"id":18471,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18471","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkinds-technospherer-inhalation-platform-utilized-fda"},"title":"MannKind’s Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™","type":{"title":"General","id":3886},"teaser":"Tyvaso DPI represents the second FDA-approved product utilizing MannKind’s Technosphere ® inhalation technology First approval of a dry powder inhaled treatment for PAH and PH-ILD Manufacturing of Tyvaso DPI for United Therapeutics underway at MannKind’s Connecticut facility with product","language":"en","releaseDate":{"dateUTC":"2022-05-24T10:00:00","date":"2022-05-24T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind’s Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18471/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-05-24T10:00:25","lastUpdatedUTC":"2022-05-24T10:00:25"},{"id":18426,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18426","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-ring-nasdaq-stock-market-opening-bell"},"title":"MannKind Corporation to Ring the Nasdaq Stock Market Opening Bell","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. and DANBURY, Conn. , May 19, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief","language":"en","releaseDate":{"dateUTC":"2022-05-19T10:00:00","date":"2022-05-19T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Ring the Nasdaq Stock Market Opening Bell","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18426/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-05-19T10:00:20","lastUpdatedUTC":"2022-05-19T10:00:20"},{"id":18421,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18421","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-announces-agreement-acquire-v-gor-insulin"},"title":"MannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device From Zealand Pharma","type":{"title":"General","id":3886},"teaser":"The once-daily insulin delivery device strengthens MannKind’s commitment to offering innovative mealtime diabetes solutions DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , May 17, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization","language":"en","releaseDate":{"dateUTC":"2022-05-17T10:06:00","date":"2022-05-17T06:06:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device From Zealand Pharma","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18421/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-05-17T10:06:18","lastUpdatedUTC":"2022-05-17T10:06:18"},{"id":18336,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18336","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participating-upcoming-conferences-2"},"title":"MannKind Corporation Participating at Upcoming Conferences","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. and DANBURY, Conn. , May 09, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it will be","language":"en","releaseDate":{"dateUTC":"2022-05-09T10:00:00","date":"2022-05-09T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Participating at Upcoming Conferences","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18336/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-05-09T10:00:23","lastUpdatedUTC":"2022-05-09T10:00:23"},{"id":18316,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18316","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2022-first-quarter-financial"},"title":"MannKind Corporation Reports 2022 First Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 p.m. (ET) 1Q 2022 Afrezza Net Revenue of $9.8 million ; +21% vs. 1Q 2021 1Q 2022 Afrezza Gross Margin 77%; Gross Profit +99% vs 1Q 2021 $233.0 million of Cash, Cash Equivalents, and Investments at March 31, 2022 Tyvaso DPI PDUFA date May 2022 DANBURY, Conn.","language":"en","releaseDate":{"dateUTC":"2022-05-05T20:00:00","date":"2022-05-05T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2022 First Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18316/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-05-05T20:00:28","lastUpdatedUTC":"2022-05-05T20:00:28"},{"id":18301,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18301","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2022-first-quarter-financial-results"},"title":"MannKind Corporation to Hold 2022 First Quarter Financial Results Conference Call on May 5, 2022","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , April 28, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time)","language":"en","releaseDate":{"dateUTC":"2022-04-28T10:00:00","date":"2022-04-28T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2022 First Quarter Financial Results Conference Call on May 5, 2022","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18301/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-04-28T10:00:14","lastUpdatedUTC":"2022-04-28T10:00:14"},{"id":18296,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18296","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-poster-15th-international-conference-advanced"},"title":"MannKind Presents Poster at 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2022) to Be Held April 27-30","type":{"title":"General","id":3886},"teaser":"Simplified 2x dose of Technosphere ® Insulin (TI) produced a statistically significant improvement in PPGE between Dose 1 & 2 from 45-120 minutes Higher dose of TI resulted in a mean difference of 52 mg/dL in PPGE at 120 minutes, with no new safety concerns WESTLAKE VILLAGE, Calif.","language":"en","releaseDate":{"dateUTC":"2022-04-27T10:05:00","date":"2022-04-27T06:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Presents Poster at 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2022) to Be Held April 27-30","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18296/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-04-27T10:05:24","lastUpdatedUTC":"2022-04-27T10:05:24"},{"id":18266,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18266","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/united-therapeutics-announces-publication-tyvaso-dpitm-breeze"},"title":"United Therapeutics Announces the Publication of Tyvaso DPI™ BREEZE Clinical and Long-term Data in the Journal Pulmonary Circulation","type":{"title":"General","id":3886},"teaser":null,"language":"en","releaseDate":{"dateUTC":"2022-04-06T10:00:00","date":"2022-04-06T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"external","link":{"id":null,"source":"url","title":"https://ir.unither.com/news/press-releases/press-release-details/2022/United-Therapeutics-Announces-the-Publication-of-Tyvaso-DPI-BREEZE-Clinical-and-Long-term-Data-in-the-Journal-Pulmonary-Circulation/default.aspx","url":"https://ir.unither.com/news/press-releases/press-release-details/2022/United-Therapeutics-Announces-the-Publication-of-Tyvaso-DPI-BREEZE-Clinical-and-Long-term-Data-in-the-Journal-Pulmonary-Circulation/default.aspx"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-04-06T19:39:08","lastUpdatedUTC":"2022-04-06T19:48:16"},{"id":18251,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18251","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-lytham-partners-spring-2022"},"title":"MannKind Corporation to Participate in the Lytham Partners Spring 2022 Investor Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. , March 28, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael","language":"en","releaseDate":{"dateUTC":"2022-03-28T10:05:00","date":"2022-03-28T06:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in the Lytham Partners Spring 2022 Investor Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18251/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-03-28T10:06:33","lastUpdatedUTC":"2022-03-28T10:06:33"},{"id":18236,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18236","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-cantor-virtual-rare-orphan"},"title":"MannKind Corporation to Participate in the Cantor Virtual Rare Orphan Disease Summit","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. , March 22, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Scientific Officer, Thomas","language":"en","releaseDate":{"dateUTC":"2022-03-22T10:05:00","date":"2022-03-22T06:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in the Cantor Virtual Rare Orphan Disease Summit","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18236/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-03-22T10:06:25","lastUpdatedUTC":"2022-03-22T10:06:25"},{"id":18231,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18231","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-oppenheimer-32nd-annual"},"title":"MannKind Corporation to Participate in Oppenheimer 32nd Annual Healthcare Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. , March 08, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael","language":"en","releaseDate":{"dateUTC":"2022-03-08T11:05:00","date":"2022-03-08T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in Oppenheimer 32nd Annual Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18231/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-03-08T11:06:26","lastUpdatedUTC":"2022-03-08T11:06:26"},{"id":18171,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18171","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2021-fourth-quarter-and-full-year"},"title":"MannKind Corporation Reports 2021 Fourth Quarter and Full Year Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 p.m. (ET) 2021 Total Revenues of $75.4 million ; +16% vs. 2020 4Q 2021 Afrezza Net Revenue of $11.3 million ; +13% vs. 4Q 2020 $260.7 million of Cash, Cash Equivalents and Investments at December 31, 2021 Commenced clofazimine Phase 1 clinical trial in 1Q","language":"en","releaseDate":{"dateUTC":"2022-02-24T21:00:00","date":"2022-02-24T16:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2021 Fourth Quarter and Full Year Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18171/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-02-24T21:02:28","lastUpdatedUTC":"2022-02-24T21:02:28"},{"id":18166,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18166","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/update-tyvaso-dpitm-new-drug-application"},"title":"Update on Tyvaso DPI™ New Drug Application","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. and DANBURY, Conn. , Feb. 24, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, was informed that the U.S.","language":"en","releaseDate":{"dateUTC":"2022-02-24T11:05:00","date":"2022-02-24T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Update on Tyvaso DPI™ New Drug Application","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18166/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-02-24T11:06:21","lastUpdatedUTC":"2022-02-24T11:06:21"},{"id":18151,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18151","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2021-fourth-quarter-and-full-year"},"title":"MannKind Corporation to Hold 2021 Fourth Quarter and Full Year Financial Results Conference Call on February 24, 2022","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Feb. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2021 fourth quarter and full year financial results, and its management will host a conference call to discuss the financial results and corporate updates at 5:00","language":"en","releaseDate":{"dateUTC":"2022-02-21T14:05:00","date":"2022-02-21T09:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2021 Fourth Quarter and Full Year Financial Results Conference Call on February 24, 2022","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18151/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-02-21T14:06:42","lastUpdatedUTC":"2022-02-21T14:06:42"},{"id":18136,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18136","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-svb-leerink-2022-global"},"title":"MannKind Corporation to Participate in SVB Leerink 2022 Global Healthcare Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. , Feb. 10, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael","language":"en","releaseDate":{"dateUTC":"2022-02-10T11:05:00","date":"2022-02-10T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in SVB Leerink 2022 Global Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18136/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-02-10T11:05:43","lastUpdatedUTC":"2022-02-10T11:05:43"},{"id":18071,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18071","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-hc-wainwright-bioconnect"},"title":"MannKind Corporation to Participate in H.C. Wainwright Bioconnect Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. , Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer Michael Castagna","language":"en","releaseDate":{"dateUTC":"2022-01-05T11:10:00","date":"2022-01-05T06:10:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in H.C. Wainwright Bioconnect Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18071/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-01-05T11:10:58","lastUpdatedUTC":"2022-01-05T11:10:58"},{"id":18066,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18066","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-extends-collaboration-thirona-bio-fibrotic-lung"},"title":"MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases","type":{"title":"General","id":3886},"teaser":"MannKind purchased an additional convertible note issued by Thirona Bio Nonclinical PD study of MNKD-501 planned, with results anticipated in 2Q 2022 MannKind’s CEO appointed as a member of the Thirona board of directors DANBURY, Conn. , Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation","language":"en","releaseDate":{"dateUTC":"2022-01-05T11:05:00","date":"2022-01-05T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18066/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-01-05T11:05:52","lastUpdatedUTC":"2022-01-05T11:05:52"},{"id":18041,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18041","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-lytham-partners-winter-2021"},"title":"MannKind Corporation to Participate in the Lytham Partners Winter 2021 Investor Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Dec. 06, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it will be participating in the","language":"en","releaseDate":{"dateUTC":"2021-12-06T11:05:00","date":"2021-12-06T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in the Lytham Partners Winter 2021 Investor Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18041/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-12-06T11:05:44","lastUpdatedUTC":"2021-12-06T11:05:44"},{"id":18026,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18026","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2021-third-quarter-financial"},"title":"MannKind Corporation Reports 2021 Third Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 p.m. (ET) 3Q 2021 Total Revenues of $22.2 million ; +45% vs. 3Q 2020 3Q 2021 Afrezza Net Revenue of $9.8 million ; +34% vs. 3Q 2020 $181.1 million of Cash, Cash Equivalents and Investments at September 30, 2021 Sale-Leaseback of Danbury manufacturing facility","language":"en","releaseDate":{"dateUTC":"2021-11-09T21:05:00","date":"2021-11-09T16:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2021 Third Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18026/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-11-09T21:11:10","lastUpdatedUTC":"2021-11-09T21:11:10"},{"id":18016,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18016","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-closes-sale-leaseback-transaction"},"title":"Mannkind Corporation Closes Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. and DANBURY, Conn. , Nov. 09, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced the closing on November 8,","language":"en","releaseDate":{"dateUTC":"2021-11-09T11:05:00","date":"2021-11-09T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Mannkind Corporation Closes Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18016/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-11-09T11:05:45","lastUpdatedUTC":"2021-11-09T11:05:45"},{"id":18001,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18001","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-data-21st-annual-diabetes-technology-meeting"},"title":"MannKind Presents Data at 21st Annual Diabetes Technology Meeting","type":{"title":"General","id":3886},"teaser":"A Technosphere ® Insulin (TI) dose – approximately double the estimated mealtime subcutaneously (SC) injection dose – reduced postprandial glucose excursions (PPGE) without any severe hypoglycemia in the first two hours Higher dose of TI resulted in approximately 50 mg/dL improvement in PPGE at 120","language":"en","releaseDate":{"dateUTC":"2021-11-05T11:05:00","date":"2021-11-05T07:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Presents Data at 21st Annual Diabetes Technology Meeting","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18001/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-11-05T11:06:00","lastUpdatedUTC":"2021-11-05T11:06:00"},{"id":17996,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17996","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2021-third-quarter-financial-results"},"title":"MannKind Corporation to Hold 2021 Third Quarter Financial Results Conference Call on November 9, 2021","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2021 third quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Tuesday, November","language":"en","releaseDate":{"dateUTC":"2021-11-02T10:05:00","date":"2021-11-02T06:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2021 Third Quarter Financial Results Conference Call on November 9, 2021","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17996/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-11-02T10:06:04","lastUpdatedUTC":"2021-11-02T10:06:04"},{"id":17976,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17976","hostedUrl":"https://investors.mannkindcorp.com/news-releases/news-release-details/progress-update-tyvaso-dpitm-new-drug-application"},"title":"Progress Update on Tyvaso DPI™ New Drug Application","type":{"title":"General","id":3886},"teaser":"Complete response received by United Therapeutics cites an open inspection issue at a third-party analytical testing center; no other deficiencies cited No issues identified regarding operations performed at MannKind’s manufacturing facility in Connecticut WESTLAKE VILLAGE, Calif.","language":"en","releaseDate":{"dateUTC":"2021-10-18T10:00:00","date":"2021-10-18T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Progress Update on Tyvaso DPI™ New Drug Application","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17976/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-10-18T10:00:56","lastUpdatedUTC":"2021-10-18T10:00:56"}],"error":null}